Amoéba S.A. (EPA:ALMIB)

Market Cap	60.76M
Revenue (ttm)	601.60K
Net Income (ttm)	-6.59M
Shares Out	68.89M
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,368
Average Volume	188,293
Open	0.8940
Previous Close	0.8820
Day's Range	0.8670 - 0.8940
52-Week Range	0.4800 - 1.4400
Beta	0.71
RSI	42.89
Earnings Date	Sep 24, 2025

About Amoéba

Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection. It has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. The company was incorporated in 2010 and is based in Chassieu, France.

• Industry: Agricultural Inputs
• Sector: Materials
• Founded: 2010
• Employees: 20
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALMIB

Financial Performance

In 2024, Amoéba's revenue was 601,600, a decrease of -9.44% compared to the previous year's 664,310. Losses were -6.59 million, -53.90% less than in 2023.